Quote this publication Share Print

CORTIMENT (budesonide), corticosteroid for local use

GASTROENTEROLOGY - New medicinal product
Opinions on drugs - Posted on Mar 29 2017

Reason for request

Inclusion

No clinical benefit demonstrated in the treatment strategy for ulcerative colitis (UC).

  

  • CORTIMENT has Marketing Authorisation for inducing remission in mild to moderate forms of ulcerative colitis (UC) for which treatment with 5-ASA is not sufficient. 
  • Its efficacy is modest, but it has fewer side effects than systemic corticosteroid therapy.
  • It has not been compared with an active treatment: 5-ASA or especially a systemic corticosteroid.

 

 


Actual benefit

Important

-


Improvement in actual benefit

V (absence)

-


Therapeutic use

-

Contact Us

Évaluation des médicaments